Abcellera Biologics Inc
NASDAQ:ABCL
Abcellera Biologics Inc
NASDAQ:ABCL
Price:
4.11 USD
1.99%
Market Closed
Updated:
May 6, 2024
Section:
Relative Value
The Relative Value of one
ABCL
stock under the Base Case scenario is
2.06
USD.
Compared to the current market price of 4.11 USD,
Abcellera Biologics Inc
is
Overvalued by 50%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ABCL
Relative Value
Base Case
2.06
USD
Overvaluation 50%
Valuation Multiples
Multiples Across Competitors
ABCL Competitors Multiples
Abcellera Biologics Inc Competitors
Abcellera Biologics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
1.2B USD | 31.4 | -8.2 | -2 | -1.8 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
222B USD | 5.2 | 37 | 22.9 | 33.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
183.3B USD | 4.2 | 22.7 | 16.5 | 20.4 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
37.3B CHF | 5.6 | 57 | 19.6 | 28.7 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
41.2B USD | 6.1 | 33.4 | 26.7 | 32.1 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
41B USD | 2.7 | 30.2 | 16.5 | 25.4 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
54.9T KRW | 14.9 | 64 | 33.7 | 48.6 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
26.7B USD | 9.1 | 46.9 | 32.5 | 39.5 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.5B USD | 7 | 33.5 | 23.5 | 26.1 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
25.8B USD | 3.1 | 37.7 | 17 | 26.2 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19B EUR | 7 | 74.5 | 32.1 | 52.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
